Home > Insider Trading > Filing (0001395064-21-000248)

Filing Details

Accession Number:: 0001395064-21-000248
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-12-09 06:04:25
Reporting Period:: 2021-12-07

Accepted Time:: 2021-12-09 06:04:25
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1845337	Day One Biopharmaceuticals Inc.	DAWN	Pharmaceutical Preparations (2834)	DE

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1002637	Millennium Pharmaceuticals Inc	40 Landsdowne Street Cambridge MA 02139	No	No	Yes	No
1395064	Takeda Pharmaceutical Co Ltd	1-1, Nihonbashi-Honcho 2-Chome Chuo-Ku, Tokyo M0 103-8668	No	No	Yes	No
1716229	Takeda Pharmaceuticals U.s.a., Inc.	95 Hayden Avenue Lexington MA 02421	No	No	Yes	No
1771657	Takeda Ventures, Inc.	9625 Towne Centre Drive San Diego CA 92121	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2021-12-07	128,745	$18.43	6,288,652	No	4	S	Indirect	See Explanation of Responses
Common Stock	Disposition	2021-12-07	58,190	$19.50	6,230,462	No	4	S	Indirect	See Explanation of Responses
Common Stock	Disposition	2021-12-08	110,338	$18.03	6,120,124	No	4	S	Indirect	See Explanation of Responses

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Explanation of Responses
No	4	S	Indirect	See Explanation of Responses
No	4	S	Indirect	See Explanation of Responses

Footnotes

Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $18.00 to $18.97. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer.
This statement is being filed jointly by Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals U.S.A. Inc., Millennium Pharmaceuticals, Inc. and Takeda Ventures, Inc.
Takeda Pharmaceutical Company Limiteds beneficial ownership of the reported securities is comprised of 6,062,900 shares of Common Stock held by Millennium Pharmaceuticals, Inc. and 57,224 shares of Common Stock held by Takeda Ventures, Inc. Millennium Pharmaceuticals, Inc. and Takeda Ventures, Inc. are each direct, wholly owned subsidiaries of Takeda Pharmaceuticals U.S.A. Inc., which is a direct subsidiary of Takeda Pharmaceutical Company Limited (72.70%) and Takeda Pharmaceuticals International AG (27.3%).
Takeda Pharmaceuticals International AG is a direct, wholly owned subsidiary of Takeda Pharmaceutical Company Limited. Each of Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals U.S.A. Inc. may be deemed to share voting and dispositive power over the shares held by Takeda Ventures, Inc. and Millennium Pharmaceuticals, Inc. Each of Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals U.S.A. Inc. disclaims beneficial ownership of the shares held by Takeda Ventures, Inc. and Millennium Pharmaceuticals, Inc. except to the extent of their pecuniary interests therein.
Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $19.00 to $19.88. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer.
Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $18.00 to $18.47. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer.